Ignite will acquire 100 of the Applied Biosystems SOLiD™ 4 Systems, the most advanced next generation DNA sequencing platform on the market, establishing the largest concentration of genetic analytical power in North America.
CARLSBAD, Calif. & FAIRFAX, Va.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ:LIFE) and the Ignite Institute for Individualized Health announced today a collaboration to create a ground-breaking genomic sequencing center at Ignite’s new facility in Northern Virginia. Ignite will acquire 100 of the Applied Biosystems SOLiD™ 4 Systems, the most advanced next generation DNA sequencing platform on the market, establishing the largest concentration of genetic analytical power in North America. The SOLiD 4 System will enable Ignite’s scientists to sequence entire genomes quicker, more accurately and more cost effectively than previously possible. The instruments will provide the throughput to fuel the research that could yield countless diagnostic, preventive and therapeutic advances.
“Since developing the equipment that enabled the initial decoding of the human genome in 2000, we have been dedicated to accelerating the technology to perform mainstream sequencing of personal genomes for research as well as translational medicine”
“Since developing the equipment that enabled the initial decoding of the human genome in 2000, we have been dedicated to accelerating the technology to perform mainstream sequencing of personal genomes for research as well as translational medicine,” said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. “That ability is now in place with the SOLiD 4 System, and we are very pleased to partner with Ignite, which is pioneering breakthrough research to make molecular medicine a reality.”
“This is truly a watershed moment for the genomic revolution that we have all been working toward,” said Ignite Founder and CEO, Dietrich Stephan, Ph.D. “Ignite was established as a non-profit collaborative enterprise to pioneer a new model for 21st century medicine through molecular scientific discovery, rapid commercialization and practical application in patient care. Through our partnership with Life Technologies, we will be able to help transform personalized medicine from promise to practice.”
With the SOLiD 4 System’s new gold standard throughput power and accuracy, scientists at Ignite will be able to efficiently and completely sequence thousands of genomes. By comparing large numbers of genomes of people with and without specific diseases, researchers can accelerate the advent of personalized and molecular medicine &ndash understanding the multiple molecular factors that cause disease.
Ignite is focusing research efforts on diseases that place the heaviest burden on personal and public health: cancers, metabolic diseases (such as diabetes), neurological disorders (such as Alzheimer’s), cardiovascular diseases (such as myocardial infarction and stroke), and pediatric afflictions (such as autism spectrum disorder).
Installations of the SOLiD 4 Systems will begin in the first quarter and continue through the balance of 2010. Revenue related to this deal is expected to be recognized over the next three years.
About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,600 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: www.lifetechnologies.com.
About The Ignite Institute
The Ignite Institute is a new non-profit institute based in the National Capital region. Ignite is the first entity to fully integrate biomedical research, development, commercialization and clinical care. The Institute is specifically focused on creating and applying the latest biomedical and technological innovations to enable truly individualized health care. With its partners, the Institute aims to elevate the quality health care and to transform health care delivery into a highly efficient, effective and affordable endeavor. For more information, visit www.igniteinstitute.org.
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6158769&lang=en
